会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Biphenyl inhibitors of carbonyl reductase
    • 羰基还原酶联苯抑制剂
    • US07781412B2
    • 2010-08-24
    • US11863243
    • 2007-09-27
    • Henry A. Charlier, Jr.Christopher K. Ewing
    • Henry A. Charlier, Jr.Christopher K. Ewing
    • A01N43/04A01N29/04A01N29/10A01N27/00A61K31/70A61K31/03A61K31/025A61K31/015
    • A61K45/06A61K31/055A61K31/085A61K31/704A61K2300/00
    • Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions and methods may be used to reduce the dosages of anthracycline anti-cancer drugs necessary to produce a desired cancer-cell-killing performance. Preferred embodiments comprise treating cancer patients with a pharmaceutical composition comprising biphenyl compounds having two halogenated (or pseudo-halogenated) and/or hydroxylated, aryl groups that are linked by a bridging atom. The preferred composition of biphenyl compound(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately than the at least one anthracycline compound. Especially-preferred biphenyl compounds include triclosan, hexachlorophene, and dichlorophene.
    • 物质组成和治疗癌症患者的方法可以预防或限制化疗期间或之后的心脏毒性,和/或可以预防或降低对蒽环类药物的抗性,这两者都被认为是由人类羰基羰基还原酶引起的。 因此,组合物和方法可用于减少产生所需癌细胞杀伤性能所需的蒽环类抗癌药物的剂量。 优选的实施方案包括用包含通过桥连原子连接的两个卤化(或假卤代)和/或羟基化的芳基的联苯化合物的药物组合物治疗癌症患者。 联苯化合物的优选组合物可以在还包含至少一种蒽环类化合物的药物组合物中施用,或者可以与至少一种蒽环类化合物分开施用。 特别优选的联苯化合物包括三氯生,六氯酚和二氯酚。